Regulatory Guidance on Home Delivery of Investigational Products (IP) in Clinical Trials

Published on 22/12/2025

Navigating Regulatory Guidance for Home Delivery of Investigational Products in DCTs

Direct-to-Patient (DTP) drug delivery is a growing practice in decentralized clinical trials (DCTs), enabling investigational products (IP) to reach participants at their homes. This model has transformed clinical trial accessibility but also brought regulatory challenges concerning product integrity, ethical conduct, and GxP compliance. In this article, we provide a comprehensive tutorial on the global regulatory landscape governing the home delivery of IPs and outline best practices for protocol and SOP alignment.

Table of Contents

Why Regulatory Guidance Is Crucial for DTP Models

Home delivery of investigational drugs is a deviation from the traditional site-based dispensing model. As such, regulators seek assurance that:

Patient safety is not compromised
Drug accountability and traceability are preserved
Cold chain and stability conditions are controlled
Data integrity and GCP principles are maintained

The shift to DTP requires proactive planning to meet pharma regulatory expectations across regions.

Global Regulatory Positions on Home Delivery of IP

1. USFDA (United States)

While the FDA does not issue DTP-specific guidance, its GCP and IP accountability requirements must be maintained. The agency accepts DTP delivery when:

The delivery process is outlined in the protocol
The IRB approves home

delivery

Cold chain and patient safety are documented

2. EMA (European Union)

The EMA issued a reflection paper during COVID-19 supporting home IP delivery, provided that:

National competent authorities approve the process
The sponsor documents rationale, oversight, and patient consent
The delivery mechanism ensures GxP compliance

3. CDSCO (India)

India’s regulatory framework for DTP is evolving. During COVID-19, CDSCO allowed home delivery of IPs under ethics committee oversight. Future protocols should:

Justify the need for home delivery
Ensure the IP meets stability and labeling requirements
Maintain temperature control and documentation

4. Other Regulatory Bodies

TGA (Australia): Permits DTP with documentation and patient consent
Health Canada: Allows DTP as long as study integrity is maintained
SAHPRA (South Africa): Evaluates DTP requests case-by-case

How to Align Protocols with Regulatory Expectations

Include Home Delivery in Protocol: Describe delivery, receipt, and storage conditions
Secure EC/IRB Approval: Home delivery should be reviewed as part of the initial or amended ethics submission
Update Informed Consent: Inform participants about shipping procedures, contact points, and what to do in emergencies
Describe IP Accountability Measures: Include chain-of-custody logs, returns process, and courier tracking

Best Practices for Regulatory-Compliant DTP Execution

Use GxP-qualified logistics vendors
Apply validation processes to temperature monitors and packaging
Maintain master shipping records in the TMF
Train site staff on roles and escalation pathways
Conduct periodic audits of the DTP process

Example SOP Elements for Regulatory-Ready DTP Delivery

Ensure your SOP includes:

Shipment initiation and approval workflow
Courier handoff and receipt confirmation
Packaging configuration (e.g., prequalified passive shippers)
Deviation handling (e.g., temperature excursion)
IMP reconciliation and returns documentation

Refer to Pharma SOPs for templates covering these aspects.

Ethical and Safety Considerations

Confirm patients can safely store and administer the IP
Offer remote training or home nurse support
Ensure clear contact options for adverse event reporting
Document patient education materials and delivery tracking logs

Technology Tools for Regulatory Compliance

Support compliance with:

eConsent platforms reflecting DTP logistics
IRT systems managing IP release and tracking
Temperature-controlled courier apps with digital logs
Central dashboards for site and sponsor oversight

Ensure these systems meet GMP compliance and data integrity requirements.

Challenges and Mitigation Strategies

Challenge: Regional regulatory variability
Mitigation: Consult local agencies before initiating DTP in each country
Challenge: Documentation burden
Mitigation: Integrate automated audit trails and cloud-based TMF platforms
Challenge: Ensuring adherence and drug stability
Mitigation: Use education, follow-ups, and validated packaging

Conclusion

As DTP becomes integral to modern clinical trials, understanding and adhering to regional and global regulatory guidance is essential. From protocol design to delivery execution, sponsors must align with ethical, safety, and accountability standards. Leveraging best practices, SOPs, and validated tools ensures a compliant, patient-centric delivery model that regulators can trust.